Executive Summary Rapport has a phase 2 (P2) readout upcoming for RAP-219, a TARPy8 AMPA receptor modulator. The preclinical results are...

This is the first position review I have written about. However, I want to start providing updates on positions and clinical trial...

A follow-up on UroGen's upcoming PDUFA

This article details why XPro and Inmune Bio will fail their Alzheimer's Phase 3 results.

Summit Therapeutics presents a buying opportunity in the long-term. Ivonescimab looks to change the cancer care landscape.

This article discussses Cybin and their upcoming readout in Genearalized Anxiety Disorder.

Vera Therapeutics has an upcoming phase 3 topline readout for atacicept.

Executive Summary - Praxis is a short going into interim results. Praxis Precision Medicines is developing Ulixacaltamide, a small...

Executive Summary Immunovant will soon publish their phase 3 results for batoclimab, a monoclonal antibody developed to treat Myasthenia...

Celcuity gedatolisib phase 3 analysis for breast cancer